---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-25-000012"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T15:00:49.847566+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Instil Bio Q4 net loss $1.82/sh; cash $115.1M; AXN-2510 NSCLC data expected 1H2025

## Summary
- GAAP net loss per share $1.82 in Q4, full year $11.39; non-GAAP $1.08 and $7.59 respectively.
- Cash, equivalents, restricted cash and marketable securities $115.1M at Dec 31, 2024, down from $175.0M year-end 2023; runway beyond 2026.
- Clinical data for AXN-2510 (PD-L1xVEGF bispecific) monotherapy in R/R NSCLC anticipated 1H2025; safety data across ~100 patients.
- ImmuneOnco to initiate 1L NSCLC patient enrollment in China Phase 1b/2 trial of AXN-2510 plus chemo in Q2 2025; US trial expected before end of 2025.
- R&D expenses $1.1M Q4 (vs $2.0M prior year); G&A $10.4M Q4; restructuring charges $0.3M Q4.

## SEC filing metadata
- accession: 0001789769-25-000012
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976925000012/0001789769-25-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976925000012/til-20250304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-25-000012
- JSON: https://secwatch.observer/filing/0001789769-25-000012.json
- Plain text: https://secwatch.observer/filing/0001789769-25-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.